You have 9 free searches left this month | for more free features.

peritoneal cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Primary Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial (Huaier granule)

Not yet recruiting
  • Primary Ovarian Cancer
  • +2 more
  • Huaier granule
  • (no location specified)
Mar 29, 2023

Cancer, Solid Tumor, Ovarian Cancer Trial in Minneapolis (FT538, Enoblituzumab)

Not yet recruiting
  • Cancer
  • +4 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Jan 24, 2023

The PIPAC PET Pilot Study, OPC-7

Not yet recruiting
  • Peritoneal Cancer
  • +3 more
  • scan
  • (no location specified)
Nov 17, 2023

A Prospective, Randomized Controlled Study of Cyclophosphamide,

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Shijiazhuang, Hebei, China
    Hebei
Aug 20, 2023

Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7

Active, not recruiting
  • Stage III Fallopian Tube Cancer AJCC v7
  • +14 more
  • Minneapolis, Minnesota
  • +1 more
Jan 27, 2023

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting
  • PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 4, 2022

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
May 12, 2023

Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer Trial (Cisplatin, No treatment)

Not yet recruiting
  • Stage III Ovarian Cancer
  • +5 more
  • (no location specified)
Dec 12, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Houston (Paclitaxel, Carboplatin, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 13, 2023

Total Management of Ovarian Cancer

Not yet recruiting
  • Tumor of Female Reproductive System
  • Ovarian Cancer
  • No intervention
  • (no location specified)
Aug 30, 2023

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • NY-ESO-1 OLP4
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Gastric Cancer, Peritoneal Carcinomatosis Trial in Vilnius (Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal

Recruiting
  • Gastric Cancer
  • Peritoneal Carcinomatosis
  • Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy
  • Vilnius, Vilniaus, Lithuania
  • +1 more
Jan 3, 2023

Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)

Recruiting
  • Mucinous Ovarian Cancer
  • +2 more
  • Bevacizumab + modified FOLFIRINOX
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Dec 25, 2022

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Boston (Microdevice)

Recruiting
  • Ovarian Cancer
  • +6 more
  • Microdevice
  • Boston, Massachusetts
  • +1 more
Jul 12, 2022

Ovarian Cancer, Ovarian Tumor, Ovarian Tumor Epithelial Trial (MIRRORS Protocol, Standard Open Cytoreductive Surgery)

Not yet recruiting
  • Ovarian Cancer
  • +5 more
  • MIRRORS Protocol
  • Standard Open Cytoreductive Surgery
  • (no location specified)
Jul 17, 2023

Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7

Active, not recruiting
  • Stage III Fallopian Tube Cancer AJCC v7
  • +14 more
  • Houston, Texas
  • +4 more
Oct 20, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer Trial in Houston (Paclitaxel/Bev (control), Paclitaxel/Bev + ZA

Recruiting
  • Epithelial Ovarian
  • +2 more
  • Paclitaxel/Bev (control)
  • Paclitaxel/Bev + ZA (experimental)
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston (Chemotherapy, Olaparib, Therapeutic

Recruiting
  • BRCA-Mutated Ovarian Carcinoma
  • +30 more
  • Houston, Texas
    M D Anderson Cancer Center
May 27, 2022

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial

Recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +32 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Post Splenectomy Infections After Surgery for Peritoneal

Recruiting
  • Post-Splenectomy Infection
  • Peritoneal Cancer
  • Questionnaire, interview or observation study
  • Basingstoke, Hampshire, United Kingdom
    The Peritoneal Malignancy Institute, Hampshire Hospitals NHS Fou
Jan 30, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate

Recruiting
  • Ovarian Cancer
  • +2 more
  • MOv19-BBz CAR T cells
  • Alpha Folate Receptor expression test
  • Philadelphia, Pennsylvania
    University of Pennsylvania Health System
Sep 12, 2022